Application of liquid biopsy for surgical management of pancreatic cancer

Published on Feb 12, 2020
· DOI :10.1002/AGS3.12317
Minako Nagai12
Estimated H-index: 12
(Nara Medical University),
Masayuki Sho41
Estimated H-index: 41
(Nara Medical University)
+ 2 AuthorsKota Nakamura5
Estimated H-index: 5
(Nara Medical University)
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest forms of cancer. Although drug development over the past decade has gradually improved the prognosis of PDAC, the prognosis remains extremely poor. The predominant determinant of a poor prognosis is that patients are already at the advanced stage when they are diagnosed. Therefore, it is essential to detect early-stage PDAC to ensure a good prognosis. However, in general, being asymptomatic at the early stage makes the detection of early-stage PDAC very difficult. Recently, much attention has been focused on the utility of a liquid biopsy as a biomarker. Theoretically, early-stage tumors can be detected even under asymptomatic conditions. A number of studies on liquid biopsies have been reported so far. Several biomarkers, including circulating tumor DNA (ctDNA), circulating tumor cells (CTCS), and exosomes, are used in liquid biopsies, with the potential to be applied to the clinical setting. Each biomarker is reported to have different utilities, such as the detection of early-stage disease, the differential diagnosis of PDAC from other types of pancreatic tumors, the prediction of the prognosis or risk of recurrence, and monitoring the treatment response. In this review, we focus on ctDNA, CTCS, and exosomes as representative liquid biopsy biomarkers and describe the specific functions of each biomarker in the treatment of PDAC. Furthermore, we discuss the application of liquid biopsies, especially for the surgical management of PDAC.
📖 Papers frequently viewed together
12 Authors (Zi Hao Qi, ..., Liang Liu)
20 Citations
51 Citations
46 Citations
#1Christopher MelaniH-Index: 9
#2Wyndham H. WilsonH-Index: 89
Last. Mark RoschewskiH-Index: 26
view all 3 authors...
: ctDNA provides an important new strategy that will aid in the treatment of non-Hodgkin's lymphoma. Immunoglobulin sequencing provides a tumor specific marker for disease activity with a sensitivity equivalent to one tumor cell per 10-6. Furthermore, it can provide an estimate of tumor bulk and tumor response dynamics during treatment. Interim monitoring can identify patients at high risk of treatment failure and surveillance monitoring can identify patients months before radiographic disease p...
8 CitationsSource
#1Gabriele De Rubis (UTS: University of Technology, Sydney)H-Index: 3
#2Sabna Rajeev Krishnan (UTS: University of Technology, Sydney)H-Index: 5
Last. Mary Bebawy (UTS: University of Technology, Sydney)H-Index: 33
view all 3 authors...
Liquid biopsies, comprising the noninvasive analysis of circulating tumor-derived material (the ‘tumor circulome'), represent an innovative tool in precision oncology to overcome current limitations associated with tissue biopsies. Within the tumor circulome, circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) are the only components the clinical application of which is approved by the US Food and Drug Administration (FDA). Extracellular vesicles (EVs), circulating tumor RNA (ctRNA)...
180 CitationsSource
#1Prashanth RawlaH-Index: 15
#2Tagore Sunkara (Mercy Medical Center (Baltimore, Maryland))H-Index: 13
Last. Vinaya GaduputiH-Index: 9
view all 3 authors...
Pancreatic cancer is the seventh leading cause of cancer-related deaths worldwide. However, its toll is higher in more developed countries. Reasons for vast differences in mortality rates of pancreatic cancer are not completely clear yet, but it may be due to lack of appropriate diagnosis, treatment and cataloging of cancer cases. Because patients seldom exhibit symptoms until an advanced stage of the disease, pancreatic cancer remains one of the most lethal malignant neoplasms that caused 432,2...
537 CitationsSource
#1Fuyuhiko Motoi (Tohoku University)H-Index: 40
#2Tomoo KosugeH-Index: 86
Last. Michiaki Unno (Tohoku University)H-Index: 67
view all 12 authors...
: A randomized, controlled trial has begun to compare neoadjuvant chemotherapy using gemcitabine and S-1 with upfront surgery for patients planned resection of pancreatic cancer. Patients were enrolled after the diagnosis of resectable or borderline resectable by portal vein involvement pancreatic cancer with histological confirmation. They were randomly assigned to either neoadjuvant chemotherapy or upfront surgery. Adjuvant chemotherapy using S-1 was administered for 6 months to patients with ...
152 CitationsSource
#1Mohamadmahdi Samandari (Imperial College London)H-Index: 9
#2María Gil Julia (Imperial College London)H-Index: 1
Last. Armando del Río Hernández (Imperial College London)H-Index: 23
view all 5 authors...
Abstract Pancreatic cancer is one of the main causes of cancer-related deaths worldwide. It is asymptomatic at an early stage, and most diagnosis occurs when the disease is already at a late stage, by which time the tumor is nonresectable. In order to increase the overall survival of patients with pancreatic cancer, as well as to decrease the cancer burden, it is necessary to perform early diagnosis, prognosis stratifications and cancer monitoring using accurate, minimally invasive, and cost-eff...
30 CitationsSource
#1Jiaming Hu (OSU: Ohio State University)H-Index: 12
#2Yan Sheng (Yantai University)H-Index: 14
Last. L. James Lee (OSU: Ohio State University)H-Index: 79
view all 6 authors...
Detection of extracellular vesicle (EV)-associated RNAs with low expression levels in early-stage cancer remains a challenge and is highly valuable. Here, we report a nanoparticle-based biochip that could capture circulating EVs without isolation, brighten encapsulated RNAs, and amplify fluorescence signals in situ in a single step. We confine catalyzed hairpin DNA circuit (CHDC) in cationic lipid-polymer hybrid nanoparticles (LPHNs) that are tethered on a chip. LPHN features a core-shell-corona...
56 CitationsSource
The earlier diagnosis of cancer is one of the keys to reducing cancer deaths in the future. Here we describe our efforts to develop a noninvasive blood test for the detection of pancreatic ductal adenocarcinoma. We combined blood tests for KRAS gene mutations with carefully thresholded protein biomarkers to determine whether the combination of these markers was superior to any single marker. The cohort tested included 221 patients with resectable pancreatic ductal adenocarcinomas and 182 control...
264 CitationsSource
#1Jun Yu (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 154
#2Yoshihiko Sadakari (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 14
Last. Michael Goggins (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 118
view all 15 authors...
Objective Secretin-stimulated pancreatic juice contains DNA shed from cells lining the pancreatic ducts. Genetic analysis of this fluid may form a test to detect pancreatic ductal neoplasia. Design We employed digital next-generation sequencing (‘digital NGS’) to detect low-abundance mutations in secretin-stimulated juice samples collected from the duodenum of subjects enrolled in Cancer of the Pancreas Screening studies at Johns Hopkins Hospital. For each juice sample, digital NGS necessitated ...
89 CitationsSource
#1Radim Moravec (NIH: National Institutes of Health)H-Index: 3
#2Rao L. Divi (NIH: National Institutes of Health)H-Index: 28
Last. Mukesh Verma (NIH: National Institutes of Health)H-Index: 29
view all 3 authors...
Detecting circulating tumor material and digital pathology imaging during pancreatic cancer progression
14 CitationsSource
#1Sushrut Kamerkar (University of Texas MD Anderson Cancer Center)H-Index: 2
#2Valerie S. LeBleu (University of Texas MD Anderson Cancer Center)H-Index: 17
Last. Raghu Kalluri (University of Texas MD Anderson Cancer Center)H-Index: 122
view all 8 authors...
Exosomes improve the delivery of siRNA to mutant KRAS in the pancreatic tumours and bypass immune clearance better than artificial liposomes, probably owing to enhanced macropinocytocis and presence of CD47 on exosomes, respectively.
856 CitationsSource
Cited By4
Last. Jaime FeliuH-Index: 28
view all 3 authors...
Pancreatic ductal adenocarcinoma (PDAC) exhibits the poorest prognosis of all solid tumors, with a 5-year survival of less than 10%. To improve the prognosis, it is necessary to advance in the development of tools that help us in the early diagnosis, treatment selection, disease monitoring, evaluation of the response and prognosis. Liquid biopsy (LB), in its different modalities, represents a particularly interesting tool for these purposes, since it is a minimally invasive and risk-free procedu...
5 CitationsSource
#1Xiao-Bo Zhang (Lanzhou University)H-Index: 1
#2Rui-Hao Zhang (Lanzhou University)H-Index: 1
Last. Hai-Yu Zhou (Lanzhou University)H-Index: 2
view all 9 authors...
Osteosarcoma (OS) is a rare soft-tissue malignant tumor with high lung metastasis and mortality rates. Preoperative chemotherapy, surgical resection of the lesion and postoperative chemotherapy are still the main treatments for osteosarcoma. The prognosis, however, is poor for patients with nonresectable, primary metastatic or relapsed disease. Recent studies have shown that targeted therapy for OS based on the characteristics of exosomes is very attractive. Exosomes are nanosized extracellular ...
2 Citations
#1Miles W. Grunvald (Rush University Medical Center)H-Index: 1
Last. Ashiq MasoodH-Index: 15
view all 5 authors...
Pancreatic cancer is a challenging disease with a low 5-year survival rate. There are areas for improvement in the tools used for screening, diagnosis, prognosis, treatment selection, and assessing treatment response. Liquid biopsy, particularly cell free DNA liquid biopsy, has shown promise as an adjunct to our standard care for pancreatic cancer patients, but has not yet been universally adopted into regular use by clinicians. In this publication, we aim to review cfDNA liquid biopsy in pancre...
6 CitationsSource
#1Francesca Simionato (University of Verona)H-Index: 14
#2Camilla Zecchetto (University of Verona)H-Index: 7
Last. Davide Melisi (University of Verona)H-Index: 31
view all 34 authors...
Background Up-front surgery followed by postoperative chemotherapy remains the standard paradigm for the treatment of patients with resectable pancreatic cancer. However, the risk for positive surgical margins, the poor recovery after surgery that often impairs postoperative treatment, and the common metastatic relapse limit the overall clinical outcomes achieved with this strategy. Polychemotherapeutic combinations are valid options for postoperative treatment in patients with good performance ...
2 CitationsSource